Company News

SOMAÍ Pharmaceuticals Newsletter - November 2021

With Germany's new government announcing that their aim is to legalise recreational cannabis, November is surely the most interesting month so far!

For SOMAÍ Pharmaceuticals, this  was a month of celebration. We are delighted & proud we achieved a huge milestone!!
After many months of hard work, we received an innovative products grant of 2.7 million euros from the Portugal 2020 committee. This grant is significant because it validates our vision and dedication to invest in R&D research and to manufacture innovative medical cannabis products for the Portuguese & European markets. 

Our CEO & Founder - Michael Sassano, referring to this, said, "Being recognized by the PT2020 assessors is an honor, which highlights the meticulous planning that goes into developing innovative cannabis medicines for the EU market. We have a long road ahead of us, but we are off to a strong start with this affirming support from the Portuguese government and the scientific community".


Somai - This month's highlights


  • We were awarded €2.7M in funding from the Portugal 2020committee for innovative products. The Company plans to develop multiple cannabinoid formulations with various delivery methods: gel caps, transdermal patches, sublingual strips, oral sprays, and drops.Portugal 2020 is a partnership agreement between Portugal and the European Commission to fund programming that helps meet national and continental economic, social, and territorial policy goals that align with sustainability and inclusivity. 
  • We are choosing our starting biomass suppliers for the first run soon, in order to start our lab-scale extraction with Lusofona University. The timing is perfect to coincide with finishing stability studies, just as we begin our industrial production. 
  • Our CEO & Founder, Michael Sassano, was part of The Great European Opportunity discussion panel at the Cannabis Europa event that took place in London earlier this month. We had the opportunity to meet plenty of industry movers and shakers and had fascinating conversations.


Here are the latest articles from our CEO, Michael Sassano: